Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

570 VANCOMYCIN
(1986): Markman M+, South Med J 79, 382 (passim)
Vasculitis (10%)
Death
(2001): Hsu SI, Pharmacotherapy 21(10), 1233
DRESS syndrome
(2007): Tamagawa-Mineoka R+, Int J Dermatol 46(6), 654 (with
teicoplanin)
(2005): Zuliani E+, Clin Nephrol 64(2), 155
Fever
(2002): Rocha JL+, Braz J Infect Dis 6(4), 196
Hypersensitivity
(2001): Hsu SI, Pharmacotherapy 21(10), 1233
(1997): Marik PE+, Pharmacotherapy 17, 1341
Injection-site thrombophlebitis
Nephrotoxicity
(2001): Tanaka M+, Yakugaku Zasshi 121(8), 621
(1999): Fanos V+, Drug Saf 20(3), 245
(1998): Elting LS+, Cancer 83(12), 2597 (17%)
(1998): Wilson AP, Int J Antimicrob Agents 10(2), 143
(1997): Fanos V+, Pediatr Med Chir 19(4), 259
(1997): Kralovicova K+, JChemother9(6), 420
Phlebitis (14–23%)
(2002): Cohen E+, J Antimicrob Chemother 49(1), 155 (14–23%)
(1998): Elting LS+, Cancer 83(12), 2597 (3%)
(1983): Farber BF+, Antimicrob Agents Chemother 23, 138
*Note: The vancomycin-induced red man syndrome is characterized
by pruritus, erythema and, in severe cases, angioedema, hypotension,
and cardiovascular collapse
VARDENAFIL
Trade name: Levitra (GSK) (Schering)
Indications: Erectile dysfunction
Category: Phosphodiesterase type 5 inhibitor
Half-life: 4–5 hours
Clinically important, potentially hazardous interactions
with: alpha blockers (alfuzosin), doxazosin, erythromycin,
fosamprenavir, indinavir, itraconazole, ketoconazole, nitrates,
ritonavir, tamsulosin, terazosin
Skin
Diaphoresis (